@article{7de1fe16bbba4d2fac35dfde1a4a2ccf,
title = "Lack of Toxicity with Long-term Isavuconazole Use in Patients with Hematologic Malignancy",
abstract = "Prolonged courses of isavuconazole (ISA) are increasingly utilized in immunocompromised patients. Toxicities have been reported with long-term use of the other triazoles. We report the first real-life tolerability data in 50 patients with hematologic malignancy receiving ≥6 months of ISA. ISA was well tolerated in our ill patient population.",
keywords = "hematologic malignancy, invasive mold infections, isavuconazole, toxicity",
author = "Dipippo, {Adam J.} and Kontoyiannis, {Dimitrios P.}",
note = "Funding Information: Potential conflicts of interest. D. P. K. acknowledges the Texas 4000 Distinguished Professorship for Cancer Research and the National Institutes of Health–National Cancer Institute Cancer Center (core support grant number 16672); has received research support from Astellas Pharma and honoraria for lectures from Merck & Co, Gilead, and United Medical; has served as a consultant for Astellas Pharma, Cidara, Amplyx, and Mayne; serves on the advisory board of Merck & Co; and has received fees from consultancy and board membership from Pfizer, Astellas, and Schering. Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Publisher Copyright: {\textcopyright} 2019 The Author(s). Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.",
year = "2019",
month = oct,
day = "15",
doi = "10.1093/cid/ciz159",
language = "English (US)",
volume = "69",
pages = "1624--1627",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",
}